You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
A Columbia University doctor is seeking to use nanopore sequencing to uncover the cause of recurrent miscarriages, reports NBC News.
By combining conventional karyotyping and low-pass sequencing, researchers found chromosomal abnormalities in 1 in 8 couples with recurrent miscarriage.
Researchers identified immune activity changes in first-trimester placenta and decidua samples profiled through single-cell RNA sequencing.
A randomized clinical trial from France revealed similar miscarriage rates in women who had cell-free DNA screening for trisomy 21 prior to invasive testing.
Noninvasive prenatal testing can uncover pregnancies at risk of miscarriage, New Scientist reports.
The firm reported $3.5 million in revenue for the three months ended Dec. 31, 2016, and $12.9 million for the full year.
The firm reported 29 percent growth in its overall testing revenues, driven mainly by higher reproductive test volume and higher per-test revenue.
CombiMatrix said the move will increase access to the test in the state for women experiencing recurrent pregnancy loss.
The company's testing was successful in more than 90 percent of cases over almost four years, and detected a wide variety of abnormalities.
The company reported an 18 percent increase in the number of reproductive health tests completed during the quarter.
Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.
A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.
In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.
According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.